Milind M. Javle, MD, on Cholangiocarcinoma: Treatment With Infigratinib

January 20, 2021 By The ASCO Post Staff

Milind M. Javle, MD, of The University of Texas MD Anderson Cancer Center, discusses phase II study results showing that the novel tyrosine kinase inhibitor infigratinib may prove to be effective in treating patients with advanced cholangiocarcinoma harboring an FGFR2 gene fusion or rearrangement (Abstract 265).

Related Content